FDA Approves Lisraya for Dermatomyositis in Adults

TUESDAY, Sept. 1, 2026-- The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment of dermatomyositis in adults.The approval was based on results from a phase 3 trial in which 241 adults with...